Skip to main content
SpringerLink
Log in

Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome

  • Original Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Objective

To assess the plasma Pentraxin 3 (PTX3) concentrations in obese children and to investigate the relationship between PTX3 levels and metabolic syndrome (MS) components.

Methods

Seventy-seven obese patients aged 10–16 y (38 girls, 39 boys) were included in the study. PTX3 levels were compared between the groups with or without MS. In addition, PTX3 was analysed separately by subgroups according to the presence of specific MS components.

Results

Plasma PTX3 concentrations were significantly higher in obese children and adolescents with metabolic syndrome than in those without MS (2.1 ± 1.2 ng/ml and 1.4 ± 0.9 ng/ml respectively; P = 0.02). Patients with low HDL levels (<40 mg/dl) had higher plasma PTX3 concentrations than those with normal HDL levels (P = 0.05). Similarly, those who had high triglyceride levels (≥150 mg/dl) had higher PTX3 levels (P = 0.01). PTX3 levels were negatively correlated with HDL cholesterol (r = −0.32, P = 0.003) among all patients.

Conclusions

PTX3 levels are higher in obese children and adolescents with metabolic syndrome than in those without MS. Thus, PTX3 levels might be a useful biomarker for children and adolescents with metabolic syndrome, dyslipidemia, and cardiovascular risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rolland-Cachera MF. Childhood obesity: current definitions and recommendations for their use. Int J Pediatr Obes. 2011;6:325–31.

    Article  PubMed  Google Scholar 

  2. Itagi V, Patil R. Obesity in children and adolescents and its relationship with hypertension. Turk J Med Sci. 2011;41:259–66.

    Google Scholar 

  3. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;12:1785–8.

    Article  Google Scholar 

  4. Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity. 2010;18:1871–4.

    Article  CAS  PubMed  Google Scholar 

  5. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, et al. Characterization of the long pentraxin PTX3 as a TNF alpha-induced secreted protein of adipose cells. J Lipid Res. 2003;44:994–1000.

    Article  CAS  PubMed  Google Scholar 

  6. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009;202:455–60.

    Article  CAS  PubMed  Google Scholar 

  7. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.

    Article  CAS  PubMed  Google Scholar 

  8. Chu SH, Park JH, Lee MK, Jekal Y, Ahn KY, Chung JY, et al. The association between pentraxin 3 and insulin resistance in obese children at baseline and after physical activity intervention. Clin Chim Acta. 2012;413:1430–7.

    Article  CAS  PubMed  Google Scholar 

  9. Shim BJ, Jeon HK, Lee SJ, Kim SS, Park MY, Lee DH, et al. The relationship between serum pentraxin 3 and central obesity in st-segment elevation myocardial infarction patients. Korean Circ J. 2010;40:308–13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Ozturk A, Mazicioglu MM, Hatipoglu N, Budak N, Keskin G, Yazlak Z, et al. Reference body mass index curves for Turkish children 6–18 y of age. J Pediatr Endocrinol Metab. 2008;21:827–36.

    Article  PubMed  Google Scholar 

  11. Hatipoglu N, Ozturk A, Mazicioglu MM, Kurtoglu S, Seyhan S, Lokoglu F. Waist circumference percentiles for 7–17-y-old Turkish children and adolescents. Eur J Pediatr. 2008;167:383–9.

    Article  PubMed  Google Scholar 

  12. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents—an IDF concensus report. Pediatr Diabetes. 2007;8:299–306.

    Article  PubMed  Google Scholar 

  13. Inokuchi M, Matsuo N, Anzo M, Takayama JI, Hasegawa T. Age- dependent percentile for waist circumference for Japanese children based on the 1992–1994 cross-sectional national survey data. Eur J Pediatr. 2007;166:655–61.

    Article  PubMed  Google Scholar 

  14. Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9:243–8.

    Article  CAS  PubMed  Google Scholar 

  15. Miyaki A, Maeda S, Yoshizawa M, Misono M, Sasai H, Shimojo N, et al. Is pentraxin 3 involved in obesity-induced decrease arterial distensibility? J Atheroscler Thromb. 2010;17:278–84.

    Article  CAS  PubMed  Google Scholar 

  16. Boehme M, Kaehne F, Kuehne A, Bernhardt W, Schröder M, Pommer W, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007;22:2224–9.

    Article  CAS  PubMed  Google Scholar 

  17. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.

    Article  CAS  PubMed  Google Scholar 

  18. Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, et al. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. Med Princ Pract. 2013;22:274–9.

    Article  PubMed  Google Scholar 

  19. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326–30.

    Article  CAS  PubMed  Google Scholar 

  20. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol. 2002;22:782–7.

    Article  CAS  PubMed  Google Scholar 

  21. Witasp A, Carrero JJ, Michaëlsson K, Ahlström H, Kullberg J, Adamsson V, et al. Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots, and weight loss. Obesity. Published Online First. 2014. doi: 10.1002/oby.20695.

  22. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221–8.

    Article  CAS  PubMed  Google Scholar 

  23. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86:S19–22.

    Article  Google Scholar 

  24. Osorio-Conles O, Guitart M, Chacón MR, Maymo-Masip E, Moreno-Navarrete JM, Montori-grau M, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, where as visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab. 2011;301:1254–61.

    Article  Google Scholar 

  25. Aydogdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Meric C. High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28:722–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Prof. Dr. Sebahattin Muhtaroglu for performing analyses in the biochemistry laboratory of Erciyes University, Medical Faculty.

Conflict of Interest

None.

Source of Funding

Health Goverment of Turkey provided financial help to conduct the study.

Author information

Authors and Affiliations

  1. Department of Pediatric Nutrition and Metabolism, Erciyes University, 38039, Kayseri, Turkey

    Fatih Kardas

  2. Department of Pediatric Endocrinology, Erciyes University, Kayseri, Turkey

    Leyla Akın, Selim Kurtoglu & Mustafa Kendirci

  3. Department of Pediatrics, State Educational and Research Hospital of the Government, Kayseri, Turkey

    Zehra Kardas

Authors
  1. Fatih Kardas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leyla Akın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selim Kurtoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Kendirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zehra Kardas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatih Kardas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kardas, F., Akın, L., Kurtoglu, S. et al. Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome. Indian J Pediatr 82, 35–38 (2015). https://doi.org/10.1007/s12098-014-1542-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-014-1542-0

Keywords

Search

Navigation